The Gynecologic Pain Management Study Act requires the Secretary of Health and Human Services to conduct a comprehensive study identifying barriers that prevent clinicians from offering and patients from accessing pain management methods during gynecologic procedures. The study must review existing literature and may include new research where gaps exist, consult with a specified set of stakeholders, and deliver findings and recommendations to relevant congressional committees within 24 months of enactment.
This is a diagnostic bill: it does not change coverage rules or create new programs directly, but it establishes a federal evidence-gathering effort that could trigger administrative or legislative action. For health systems, payors, device manufacturers, and reproductive-health providers, the study’s scope and recommendations will shape future reimbursement, training, and procurement priorities—especially where equity and access gaps are identified.
At a Glance
What It Does
The bill directs HHS to perform a comprehensive assessment of barriers to offering and accessing pain management for gynecologic procedures, including a literature review and, if needed, new research. It mandates stakeholder consultation and requires a report to two congressional committees with findings and recommendations within 24 months.
Who It Affects
Directly affects reproductive health clinicians (OB/GYNs, family planning providers, outpatient proceduralists), federal and state payors (Medicaid, Medicare, private insurers), device manufacturers and innovators, and patients—particularly those in marginalized communities who report disparities in procedural pain care. Indirectly affects health systems, training programs, and policy-makers who will act on the study’s recommendations.
Why It Matters
The bill fills a targeted evidence gap about why pain control during routine gynecologic procedures often falls short, linking clinical practice barriers to policy levers such as coverage, guidelines, and training. Its findings could prompt CMS or private payor changes, inform workforce and education priorities, and reshape where grant or regulatory attention is focused on equity and device access.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act sets up a bounded but flexible research mandate for HHS: identify why patients undergoing gynecologic procedures do not consistently receive effective pain management and why clinicians may not offer it. "Gynecologic procedures" is left undefined in the text, which gives HHS latitude to determine the roster of procedures to study—examples likely include IUD insertion, endometrial biopsy, hysteroscopy, dilation and curettage, cervical procedures, and colposcopy. The study must begin with a systematic review of existing literature and may commission new primary research if the literature is insufficient.
HHS must formally engage a mixed group of stakeholders the bill lists by category—patients and advocacy groups, licensed reproductive health providers, professional societies, public health and health equity experts, and medical device makers. That list signals the study should blend quantitative analysis (claims, EHRs, utilization data) with qualitative input (surveys, focus groups, expert panels) so that both system-level constraints and lived‑experience barriers are captured.The bill gives HHS 24 months after enactment to deliver a report to the House Committee on Energy and Commerce and the Senate Committee on Health, Education, Labor, and Pensions.
The required report must present findings and may include recommendations for administrative or legislative action—ranging from changes in reimbursement policy, provider training priorities, device coverage guidance, to targeted research or grants. The Act also defines "pain management methods" broadly as methods to prevent, reduce, or manage physical pain associated with a medical procedure, which allows the study to consider pharmacologic, regional/local anesthesia, sedation, device-based options, and non-pharmacologic techniques.Because the bill is a study directive rather than a funding authorization, its practical impact will depend on how HHS designs the research, what data sources it uses (for example, Medicaid and private claims, EHR data, patient-reported outcomes), and whether Congress or agencies act on the report’s recommendations.
The inclusion of device manufacturers among stakeholders flags that the study is expected to examine technological solutions alongside training and coverage barriers, while the explicit call for health equity expertise requires attention to disparities in access and outcomes.
The Five Things You Need to Know
The bill requires HHS to submit a written report to the House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions Committee no later than 24 months after enactment.
The study must assess barriers affecting both providers offering pain management and patients accessing it, allowing HHS to analyze supply‑side and demand‑side constraints.
HHS must consult six stakeholder categories: patients and advocacy groups; licensed reproductive health providers; professional medical societies; public health experts; health equity experts representing marginalized communities; and medical device manufacturers and innovators.
The statute instructs HHS to review existing literature and, if necessary, conduct new research—giving the agency discretion to commission primary data collection, submit requests for proposals, or partner with research institutions.
The bill defines "pain management methods" as methods or strategies to prevent, reduce, or manage physical pain associated with a medical procedure, enabling a broad review that can include pharmacologic, regional/local anesthesia, sedation, device-based, and non‑pharmacologic interventions.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the Act the name "Gynecologic Pain Management Study Act." This is purely nominal but frames the statute’s focus; it signals intent and scope for HHS and stakeholders when the agency sets the study’s parameters.
Mandated study to identify barriers
Directs the Secretary of HHS to conduct a comprehensive study assessing barriers to offering and accessing pain management during gynecologic procedures. Practically, this provision tasks HHS with defining which procedures and which pain-management modalities to examine, choosing study methods (systematic review, secondary data analysis, primary research), and deciding how to measure "barriers"—from reimbursement and coding obstacles to clinician training gaps and supply‑chain constraints.
Required stakeholder consultation
Requires HHS to consult named stakeholder categories. That statutory list constrains—but does not micromanage—engagement: HHS must include patient voices, clinical societies, public health and equity experts, and device makers, which shapes both the questions asked and the solutions considered. The mandate implies mixed‑methods engagement (surveys, focus groups, advisory panels) and raises questions about conflict‑of‑interest management when industry representatives participate.
Report and recommendations to Congress
Requires a deliverable report within 24 months with study findings and any recommendations for administrative or legislative action. This provision gives HHS a clear deadline and directs the agency to translate evidence into possible policy options—examples include CMS guidance, Medicaid coverage clarifications, provider training initiatives, or recommendations for statutory changes to reimbursement or grant programs.
Definitions
Defines key terms narrowly: "pain management methods" means methods or strategies to prevent, reduce, or manage physical pain associated with a medical procedure, and "Secretary" means the HHS Secretary. The broad definition of pain management gives HHS explicit authority to evaluate a wide array of interventions, while the straightforward definition of "Secretary" avoids ambiguity about which agency unit will lead.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients undergoing gynecologic procedures—especially those in marginalized communities—stand to benefit from a study that could surface access gaps and lead to coverage, training, or clinical‑practice changes that increase access to effective pain control.
- Reproductive health providers and clinics could benefit if the report yields clearer reimbursement guidance, training support, or best‑practice toolkits that make offering pain management less burdensome and more standardized.
- Public health and equity advocates will gain an evidence base to press for targeted interventions (Medicaid policy changes, community outreach) where disparities in pain control are documented.
- Medical device manufacturers and innovators could benefit commercially if the study identifies unmet needs where device‑based pain control has demonstrated benefit or where coverage uncertainty limits market uptake.
- Professional medical societies may use the study’s findings to update clinical guidelines, CME curricula, and competency standards related to procedural pain control.
Who Bears the Cost
- HHS will bear the resource and implementation burden of conducting the study—designing protocols, procuring data, managing stakeholder engagement, and drafting the report—unless Congress provides specific funding for new research components.
- Federal and state payors may face pressure (and eventual costs) if the study recommends coverage expansion for certain pain‑management methods, leading to higher claims for covered procedures or devices.
- Health systems and clinics could incur compliance and operational costs if recommendations call for training, staffing changes, or new equipment to deliver expanded pain-management options.
- Device manufacturers will face scrutiny over conflicts of interest if they participate in stakeholder processes, and may face requests to supply data or change pricing/coverage approaches based on study findings.
- Academic and research institutions could face opportunity costs if HHS contracts new primary research but limits funding or dictates narrowly defined study designs.
Key Issues
The Core Tension
The central tension is between generating rigorous, representative evidence and doing so quickly and cheaply: the bill asks HHS to produce actionable findings within two years while leaving funding and methodological choices to the agency. That forces a trade‑off between depth (primary, prospective research that can capture marginalized populations and patient‑reported pain outcomes) and speed/resources (relying on existing literature and claims data that may undercount the very disparities the study aims to reveal).
The bill is diagnostic rather than prescriptive, but that creates two linked implementation challenges. First, the statute’s usefulness depends entirely on how HHS defines scope and methods: a narrowly scoped literature review will surface less actionable evidence than a mixed‑methods program that combines claims analysis, EHR data, and well‑designed primary studies.
The text allows "new research" but does not appropriate funds; if HHS lacks resources it may rely on existing datasets and stakeholder reports, which can bias findings toward better‑documented populations and settings.
Second, the mandated stakeholder list includes industry alongside patients and equity experts, which raises governance questions. Device makers can provide important technical data but also have commercial incentives.
The statute does not set conflict‑of‑interest rules for panels or data-sharing terms, nor does it require HHS to prioritize certain evidence types. Finally, the bill leaves "gynecologic procedures" undefined; HHS must choose a scope that balances comprehensiveness with feasibility, but that choice will materially influence both findings and policy recommendations.
Operationally, the 24‑month deadline is achievable for a high‑quality literature review and targeted secondary analyses but tight for substantive primary research that requires IRB approval, multisite recruitment, or prospective data collection. The absence of a funding authorization means recommendations that require new spending or reimbursement changes will trigger a separate political and appropriations process to be realized.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.